Kimmig Rainer, Buderath Paul, Mach Pawel, Rusch Peter, Aktas Bahriye
Department of Gynecology and Obstetrics, West-German Cancer Center, University of Duisburg-Essen, Essen, Germany.
J Gynecol Oncol. 2017 May;28(3):e41. doi: 10.3802/jgo.2017.28.e41. Epub 2017 Mar 21.
Whether pelvic and para-aortic lymphadenectomy is of therapeutic benefit in advanced ovarian cancer will remain unclear until the publication of the Arbeitsgemeinschaft Gynäkologische Onkologie lymphadenectomy in ovarian neoplasms (AGO LION) trial. In early ovarian cancer, however, lymphadenectomy seems mandatory for diagnostic and also therapeutic reasons.
Complete systematic lymphadenectomy is accompanied by morbidity which may be reduced by sentinel node biopsy already established for several solid tumors. In ovarian cancer there are 2 main pathways in lymphatic drainage: along the ovarian vessels to the para-aortic nodes and the uterine vessels to the iliac lymph compartments. Following injection of radioactive dye into the ovarian ligaments this could be confirmed suggesting that there is bidirectional flow at this level of the ovarian and uterine lymphatic pathways. Indocyanine-green-guided (ICG) injection to the uterine corpus seems to be equally effective in labelling the "uterine Müllerian" and the "ovarian mesonephric" lymphatic drainage of the ovary.
This technique was applied and will be outlined in the video showing the procedure with respect to the para-aortic lymphatic drainage. Isolated sentinel node biopsy and tumor excision will not resect the organ compartment together with its super-ordinated draining lymphatic system at risk.
Thus, the authors suggest to remove the malignancy together with its draining lymphatic vessels and at least the first 2 sentinel nodes in each channel en bloc; we propose to analyze this procedure consistent with the ontogenetic approach with respect to diagnostic accuracy and loco-regional control. This could potentially avoid most of systematic lymphadenectomies in early ovarian cancer.
在妇科肿瘤学 Arbeitsgemeinschaft 卵巢肿瘤淋巴结切除术(AGO LION)试验发表之前,盆腔和腹主动脉旁淋巴结切除术对晚期卵巢癌是否具有治疗益处仍不明确。然而,在早期卵巢癌中,出于诊断和治疗原因,淋巴结切除术似乎是必要的。
完整的系统性淋巴结切除术会伴随一定的发病率,而针对多种实体瘤已确立的前哨淋巴结活检可能会降低这种发病率。在卵巢癌中,淋巴引流有两条主要途径:沿卵巢血管至腹主动脉旁淋巴结,以及沿子宫血管至髂淋巴间隙。向卵巢韧带注射放射性染料后,这一点得到了证实,表明在卵巢和子宫淋巴途径的这一水平存在双向流动。向子宫体注射吲哚菁绿引导(ICG)似乎在标记卵巢的“子宫苗勒氏”和“卵巢中肾”淋巴引流方面同样有效。
应用了该技术,相关视频将展示腹主动脉旁淋巴引流的手术过程。孤立的前哨淋巴结活检和肿瘤切除不会连同其上级引流淋巴系统一起切除有风险的器官区域。
因此,作者建议将恶性肿瘤连同其引流淋巴管以及每个通道中至少前两个前哨淋巴结整块切除;我们建议按照个体发生学方法分析该手术,以提高诊断准确性和局部区域控制效果。这有可能避免早期卵巢癌中的大多数系统性淋巴结切除术。